Cita APA

Racioppi, M., Di Gianfrancesco, L., Ragonese, M., Palermo, G., Sacco, E., & Bassi, P. F. (2018). ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer.

Chicago Style Citation

Racioppi, Marco, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco, i Pier Francesco Bassi. "ElectroMotive Drug Administration (EMDA) of Mitomycin C As First-line Salvage Therapy in High Risk “BCG Failure” Non Muscle Invasive Bladder Cancer: 3 years Follow-up Outcomes." BMC Cancer 2018.

Cita MLA

Racioppi, Marco, et al. "ElectroMotive Drug Administration (EMDA) of Mitomycin C As First-line Salvage Therapy in High Risk “BCG Failure” Non Muscle Invasive Bladder Cancer: 3 years Follow-up Outcomes." BMC Cancer 2018.